Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
Momentum Public Relations
Press Release: March 14 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug (delta-9-tetrahydrocannabinol 9.5% and cannabidiol 2.5%) for the treatment of complex regional pain syndrome (CRPS). The Orphan Drug Designation was granted for the active moiety of the drug PPP001 and not the formulation.
The FDA Orphan Drug Designation program provides orphan status to drugs intended to treat rare diseases or disorders that affect less than 200,000 people in the USA. This designation gives Tetra a seven-year marketing exclusivity, after drug approval by the FDA, and provides Tetra potential incentives such as access to federal grants and tax credits as well as a waiver of Prescription Drug User Fee Act filing fees.
Tetra successfully completed a placebo-controlled Phase 1a and 1b study of PPP001 in healthy volunteers and demonstrated that PPP001 can be safely consumed. “We are pleased to receive FDA Orphan Drug Designation for PPP001 and we look forward to discussing the clinical program with the US FDA that will be used to demonstrate the safety and efficacy in patients suffering from CRPS,” said Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer of Tetra.
According to the USA National Institute of Health, “complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb (arm, leg, hand, or foot) usually after an injury. CRPS is believed to be caused by damage to, or malfunction of, the peripheral and central nervous systems. CRPS is characterized by prolonged or excessive pain and changes in skin color, temperature, and/or swelling in the affected area.”
Appointment of a New Director – Tetra also announced the appointment of a new Director, Mr. Benoit Chotard, effective immediately. Mr. Chotard was previously a member of the Board of Directors from September 2016 to July 2017, he left for personal reasons, no longer applicable, and is pleased to come back. “We are glad to welcome back Mr. Chotard to the board and we look forward to working closely with him in building Tetra as a leading biopharmaceutical organization,” said Andre Rancourt, Chairman of Tetra Bio-Pharma. “Mr. Chotard’s tremendous experience as an advisor of publicly listed companies will be a huge addition to our team. His local and international network will be a key factor in the Company’s growth.”
Benoit Chotard is a corporate finance & development executive who has over 20 years of international corporate finance, management and public market expertise. Previously, Mr. Chotard was employed as managing partner at Capital Force United, as President & CEO, and Director of Orletto Capital Inc., Vice-president Corporate Development for Pakit Inc., Senior Vice-president Finance Corporate Development and acting as Chief Financial Officer for CANTRONIC Systems (Canada) Inc., Vice-President Chief Financial Officer of Victhom Human Bionics, and spent eight years as Head of the Technology Investment Group of National Bank Financial Inc.
Mr. Chotard has been a Member of “Ordre des ingénieurs du Québec” since 1989 and obtained a bachelor’s degree in Chemical Engineering (1989) and a MBA (1993) from the Université de Sherbrooke.
About PPP001:
PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
- Published in Tetra Bio Pharma
Relevium Announces Initial Launch of Hempco’s PlanetHemp® in the USA
Momentum Public Relations
Press Release: March 13 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (“Relevium”) and Hempco Food and Fiber Inc (TSX VENTURE:HEMP) (‘Hempco’) are pleased to announce the launch of five PlanetHemp® products in the U.S., which are expected to be live the week of March 19, 2018.
Highlights
- Initial launch of five (5) products under the PlanetHemp® brand
- Subsequent additions to the PlanetHemp® product offering in planning stages
- Relevium will launch a Bioganix® Hemp-based Vegan Omega Essential Fatty Acids
Aurelio Useche, CEO of Relevium stated: “Increasing market awareness of the beneficial properties of hemp are creating strong momentum in the food and food additives space. Through our exclusive partnership with Hempco, giving us access to its PlanetHemp® brand, we are exceptionally well positioned to gain market share in this rapidly growing segment of the market. The launch of these products in the United States via Amazon, and in the future on other main sites, such as Jet.com, is an important milestone for both companies. We anticipate this will drive considerable growth and create significant shareholder value for both companies.”
Diane Jang, CEO of Hempco Canada stated: “We are pleased with Relevium’s initiatives towards the launch of the PlanetHemp® products in the U.S. Market. This relationship adds a significant presence on the most important eCommerce channels in the U.S. and we look forward to building a successful long-term and expanding relationship with Relevium.”
The initial launch will comprise of five (5) products, including PlanetHemp® Protein Superfoods and Hemp Seeds.
Relevium will also be launching a Hemp-based Vegan Omega Essential Fatty Acids under its Bioganix® brand.
About Hemp and Derivatives
Hemp is a distinct variety of the Cannabis Sativa plant that is grown specifically for its derived products and applications. Hemp has gained considerable popularity because of its health and wellness effects on humans and pets, primarily due to its well-balanced nutritional value, alkalinity and the presence of cannabidiol, a compound known to promote and support overall health.
According to a recent article published by Forbes, hemp-derived cannabidiol (CBD) is projected to be a billion-dollar market in just three years, according to a new report by Brightfield Group. The data company estimates that hemp CBD sales have already hit $170 million in 2016 and a 55% compound annual growth rate over the next five years will cause the market to crack the billion-dollar mark.
About Hempco
For more than 12 years Hempco has been a trusted and respected pioneer, innovator and provider of premier hemp seed foods. Hempco is committed to developing hemp foods, hemp fiber and hemp nutraceuticals, a “tri-crop” opportunity for producers and processors. Hempco is expanding its processing ability to meet global demands in a 56,000sq. ft. facility located at Nisku, Alberta. Hempco’s common shares trade on the TSX Venture Exchange under the symbol “HEMP”.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC. | HEMPCO FOOD AND FIBER INC. |
Aurelio Useche | Diane Jang |
President and CEO | CEO |
Relevium Technologies Inc.
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
Hempco Food and Fiber Inc.
John Ross
Chief Financial Officer
+1.647.291.4234
john@hempcocanada.com
- Published in Relevium Technologies
Tetra Bio-Pharma Takes First Steps into European Medical Cannabis Market
Momentum Public Relations
Press Release: March 6 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF) announced today that its partner PS Innovations will be seeking CE Marking for its Rx Princeps™ Inhalation Device, thereby opening the door to Tetra’s commercialization efforts in Europe.
Tetra’s development and manufacturing partner, PS Innovations, will be seeking CE Marking for Tetra’s Rx Princeps™ Inhalation Device, which is used in conjunction with a dried loose cannabis, such as Rx Princeps™, to provide relief for advanced cancer pain and non-cancer pain patients.
Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps™ is composed of the same medical cannabis blend used to produce PPP001, the lead product in Tetra’s pipeline of five cannabinoid-based prescription drugs seeking Health Canada and FDA approval in Canada and the United States.
“CE marking” is the process that guarantees a product’s conformity to the European regulations and is required to allow Tetra to commercialize and trade on the European and European Economic Area markets. Under the European regulation, Rx Princeps™ Inhalation Device will be considered as a Class 1 Medical Device.
“This is significant for Tetra since there are a number of European countries, with Germany at the forefront, where medical cannabis has been legalized,” said Bernard Fortier, Tetra’s CEO.
The annual potential estimate for the medical cannabis European market value is EUR35.7b, according to the European cannabis report from a Prohibition Partners November 2017 report. In the US, the consumption devices market grew 116.5% in 2016 (year over year growth, New Frontier data report 2016).
“We know that more than half the people who consume cannabis choose to smoke it,” said Mr. Fortier. “This first step into Europe with a strong partner like PS Innovations solidifies our strategic focus on global expansion and potentially offers the European medical community and their patients the most innovative therapeutic options.”
PS Innovations will ensure that the Rx Princeps™ Inhalation Device meets all the relevant Essential Requirements of the European Medical Device Directive and then register the product with the Competent Authority and affix the CE marking.
About PS Innovations:
PS Innovations was created in 2017 to bring new devices for the use of Cannabis products, and the creation of machinery dedicated to the manufacture of Cannabis based dosage forms. Current devices on the market today are designed for the use of tobacco, and not cannabis derived products. Cannabis is unique in many ways, and does not always behave in the manner that tobacco products do. PS Innovations has been able to bring to the market a Class I medical device, namely an inhalation device (pipe) specific to the ACMPR [Access to Cannabis for Medical Purposes Regulations] use of dry loose cannabis.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, failure to obtain sufficient financing to execute the Corporation’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Corporation’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
investors@tetrabiopharma.com
1 (438) 899-7575
- Published in Tetra Bio Pharma
Relevium Provides H2 Guidance for Bioganix, Acquisitions and Legal Hemp Derivatives
Momentum Public Relations
Press Release: March 2 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to provide guidance on its strategy for its core e-commerce business for the second half of fiscal year ending June 30, 2018.
Highlights
- Bioganix® strategy and revenue expansion
- Official launch of Planet Hemp products
- Introduction and launch of Heart and Eye Health Omega 7 products
- Guidance on legal hemp derivatives for nutraceutical and skin care
- Launching of first pet care product
- European expansion of Bioganix brand
- Strategy and guidance for actionable M&A opportunities
Bioganix Strategy and Revenue Expansion
The Company has shifted its focus from daily operations optimization to increasing brand value. As such, Bioganix® is undergoing a major brand facelift which will better represent the values presentation and promise to our growing customer base. Words like Credibility, Quality, Trust, Elevated, Accessible, Centered, Confident, Wellness and Self-Actualization will be at the core of the new presentation to the market, with the objective at seeking higher conversion rates and brand loyalty within a more informed and wider audience base.
Relevium has been working with a newly extended supplier base and intends to launch sixteen (16) new products under the Bioganix® product brand before June 30, 2018. These new products will represent the first set of products launched entirely by the Relevium Operations Team since taking control of the business in July of 2017.
Official Launch of Planet Hemp Products
Since signing the exclusive product agreement with Hempco and PlanetHemp, the Company has been working closely with the team at Hempco to launch the PlanetHemp brand in Amazon US and UK. The team at Relevium will be launching five (5) PlanetHemp products in in H2 2018.
Abis Hussain, Senior Marketing Officer at Relevium stated: “We are seeing a huge appetite for hemp nutrition, skin care and hemp derived CBD products selling in legal jurisdictions online, both in the UK and US.” Mr. Hussain continued: “With increasing media exposure and regulatory changes, consumers are looking for hemp-based products to add them to their wellness programs. We feel that we are in the right position to capitalize on this segment.”
Introduction and launch of Heart and Eye Health Omega 7 products
Following the signing of the exclusivity agreement with Tersus for Provinol Ultra-Purified Omega 7products, the Company is in the process of building a premium brand and online assets for a new line of research-based vegan and fish oil based product line. The Omega 7 products for Heart and Vision will be the first of a series of products that will be launched and marketed as a premium product.
Mr. Hussain stated: “Omega products sell extremely well online. We are well positioned with exclusive and premium products like Ultra-Purified Omega 7, and our team is confident that a premium brand strategy will deliver optimal value to Relevium. The new premium brand will allow us to market products to a new demographic and market segment that is diversified from the Bioganix® core brand.”
Guidance on legal hemp derivatives for nutraceutical and skin care
Relevium has seen an increase in online content and traffic for hemp and hemp derivatives such as CBD. The market place is changing fast and the rate of adoption as well. In advance of fully launching products, brands and new business segments, the Company has begun accumulating a portfolio of domain names and is also building online assets for an elevated an trusted brand in the space.
The Company has been actively qualifying various suppliers, vendors, products and research partners in the space and believes that launching products within the legal hemp derivative market in H2 2018 is feasible.
Management is working with its legal counsel to ensure full compliance within a fast-evolving space. In order to ensure compliance for online retail, the company has engaged experts to build a private Blockchain with the objective of supporting and ensuring compliance in the entire supply chain.
Mr. Useche stated: “We have been actively monitoring and working in this market. We are cognisant that e-commerce for hemp and hemp derivatives for over-the-counter and prescription formulations will be an enormous market. We believe to have the initial based to ensure we position an elevated, trusted and compliant Relevium brand in this space.”
Execution of product launches in the hemp, hemp derivatives including CBD will be dependent on compliance with laws and regulations in each jurisdiction and each e-commerce platform where products are to be offered.
Launching of first pet care product
Relevium previously announced the creation of a segment of pet-focused products. The Company expects to launch its first products to include research-based joint and brain health formulations, both products currently trending online in 2018.
European expansion of Bioganix brand
The Company has been working on building out distribution for the European Union (“E.-U.”), notably in the United Kingdom, Germany, France, Spain and Italy. Initially focused on the geographical expansion of the BioGanix brand, Relevium will launch brands and products in the E.-U. as permitted by law.
Strategy and guidance for actionable M&A opportunities
The Company’s acquisition strategy is now focused on three main parameters: (1) strategic fit, (2) diversification and (3) accionability, the latter greatly dependent on market conditions, deal structure and our own valuation in the market. The main objective is ensure that we deliver a target that adds value to the portfolio and is well structured to limit the dilution effect.
The pipeline for acquisitions has been as high as USD 120,000,000 in cash flows to acquire. Depending on marketplace fluctuations, the pipeline is rarely lower than USD 50,000,000 in cash flow to acquire.
Mr. Useche stated: “The acquisition parameters from inception have been clear: we want to buy assets with high margins and pay low multiples, but there must be strategic fit and brand value add to our current business. We remain very active and in discussions but have yet to find the perfect candidate for our second acquisition that meets our more stringent selection process.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
Relevium Technologies Inc.
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies
Arev Nutrition Sciences Inc. Announces Derek Sider as CFO
Momentum Public Relations
Press Release: February 8 2018
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CSE – AREV ), is pleased to announce Derek Sider has joined the Company as Chief Financial Officer (“CFO”), effective immediately.
Due to the current transaction between the Company and We Grow BC Ltd (“WGBC”), Long Trinh, currently Chief Financial Officer of AREV, has resigned to focus his attention on matters relating to We Grow BC Ltd and closing the transaction with AREV announced on January 17, 2018. The Company is pleased to announce that Derek Sider has been appointed, effective immediately, as Chief Financial Officer (“CFO”).
Derek Sider (Derek) is an experienced financial profession with over 17 years in various international business roles.
Most recently Derek spent 6 years in the mining industry in management roles ranging from M&A to corporate administration and corporate tax. He has participated on a variety of international acquisitions, divestitures, joint ventures and other mining deals with values up to $2 billion. His experience includes corporate finance, corporate tax, securities and corporate law matters, public and private debt, deal negotiation, and corporate structuring.
Prior to that, Derek spent 9 years at PricewaterhouseCoopers, in a number of roles including International Tax in Vancouver and Capital Markets in New York, progressing to the senior manager level.
He has served on a number of non-profits boards, most recently as Treasurer/Finance Committee Chair at the Association of Neighborhood Houses, one of BC’s largest and oldest charities.
Derek is a designated Chartered Professional Accountant (CGA) with a Masters in Science (Tax) with honors and is currently a candidate for a Masters in Business Law (Osgoode Law).
The Company is also pleased to appoint Denby Greenslade as Corporate Secretary of AREV Nutrition Sciences Inc., effective immediately. Ms. Greenslade has over 15 years of corporate secretarial, corporate governance, and securities regulation experience with a focus on the neutraceutical and mining sector in Canada and Mexico. She has served in several senior management and executive roles for companies listed on the Toronto Stock Exchange, TSX Venture Exchange and Canadian Stock Exchange. During her career, she has been involved in numerous transactions and financings, and has led the evaluation, design, implementation and monitoring of governance programs for several junior mining companies.
Further, the Company has hired a consultant with over 12 years of management experience at TELUS to head a number of important Human Resources initiatives. Amongst other things, the consultant will assist with sourcing and place strategic individuals in key roles moving forward.
The Company, effective immediately, has issued 405,000 stock options to Officers and consultants of the Company at a price of $0.56 for a period of 5 years from the issuance date. 25,000 of these options will vest immediately with the remaining 380,000 options on a 2 year vesting schedule: 1/3 immediately, 1/3 at the 1 year mark and the final 1/3 at the end of the second year.
For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com.
On behalf of the Board,
Stephane Maher
Chief Executive Officer & Director
About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. (“AREV”) produces and delivers functional ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido. .
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2018 TheNewswire – All rights reserved.
- Published in AREV Nutrition Sciences
- 1
- 2